TY - JOUR T1 - Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain JO - Archivos de Bronconeumología T2 - AU - Monteagudo,Mònica AU - Nuñez,Alexa AU - Solntseva,Iryna AU - Dhalwani,Nafeesa AU - Booth,Alison AU - Barrecheguren,Miriam AU - Lambrelli,Dimitra AU - Miravitlles,Marc SN - 03002896 M3 - 10.1016/j.arbres.2020.07.032 DO - 10.1016/j.arbres.2020.07.032 UR - https://www.archbronconeumol.org/en-treatment-pathways-before-after-triple-articulo-S0300289620302672 AB - BackgroundRecent data from real world clinical practices on the use of Triple Therapy (TT) in patients with COPD are scarce. MethodsObservational population-based study with longitudinal follow-up in patients with COPD identified in a primary care electronic medical records database in Catalonia, covering 80% of the general population. The aims were to characterize COPD patients who initiated TT and to describe treatment pathways before and after TT initiation. Time to and probability of step down or complete discontinuation of TT was described using restricted mean survival time and Kaplan–Meier analysis. ResultsA total of 34,018 COPD patients initiated TT during the study period. Of them, 23,867 (70.1%) were GOLD A/B. 18,453 (54.2%) were non-exacerbators, 9931 (29.2%) infrequent exacerbators, 5634 (16.5%) frequent exacerbators and 1923 (5.6%) had asthma-COPD overlap. Drugs most frequently used prior to initiation of TT were long-acting antimuscarinics (22.5%) and combination of long-acting beta2 agonists/inhaled corticosteroids (15.2%). A total of 11,666 (34.3%) stepped down and 1091 (3.2%) discontinued TT during follow-up. Step down following TT was more likely in patients with severe COPD, especially during the first year; however, discontinuation was more common among patients with mild COPD. ConclusionMost patients initiating treatment with TT were non exacerbators and continued on the same treatment over time regardless severity of disease. Stepping down was more frequent in severe patients, while discontinuation was more common among mild patients. Overall, it appears that TT is extensively used in primary care for treatment of patients with COPD. ER -